These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 16911189

  • 1. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
    Ogata H, Koiwa F, Ito H, Kinugasa E.
    Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
    [Abstract] [Full Text] [Related]

  • 2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU.
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB.
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [Abstract] [Full Text] [Related]

  • 5. Clinical experience with cinacalcet HCl.
    Ureña Torres P.
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
    [Abstract] [Full Text] [Related]

  • 6. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L, Carboni C, Stipo L, Malaguti V, Ferrari F, Graziani R, Arletti S, Graziosi C.
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
    Iseki K.
    Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, Leavey S, Rix M, Os I, Saha H, Ryba M, Bencova V, Baños A, Zani V, Fouque D.
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [Abstract] [Full Text] [Related]

  • 10. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ.
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M, Pontoriero G, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Zani VJ, Carter D, Messa P.
    Nephron Clin Pract; 2009 Nov; 112(1):c41-50. PubMed ID: 19365139
    [Abstract] [Full Text] [Related]

  • 13. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.
    Tominaga Y, Matsuoka S, Uno N, Sato T.
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S21-6. PubMed ID: 19032523
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of cinacalcet in treating secondary hyperparathyroidism.
    Brommage D, Gallgano C.
    Nephrol Nurs J; 2005 Oct; 32(2):229-31. PubMed ID: 15889812
    [Abstract] [Full Text] [Related]

  • 18. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
    Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Wheeler DC, Parfrey PS.
    Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
    [Abstract] [Full Text] [Related]

  • 19. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG.
    N Engl J Med; 2004 Apr 08; 350(15):1516-25. PubMed ID: 15071126
    [Abstract] [Full Text] [Related]

  • 20. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
    Li D, Shao L, Zhou H, Jiang W, Zhang W, Xu Y.
    Endocrine; 2013 Feb 08; 43(1):68-77. PubMed ID: 22669774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.